Efficacy and Safety of Bepirovirsen in Chronic Hepatitis B Infection

In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.

Saved in:
Bibliographic Details
Published inThe New England journal of medicine Vol. 387; no. 21; pp. 1957 - 1968
Main Authors Yuen, Man-Fung, Lim, Seng-Gee, Plesniak, Robert, Tsuji, Keiji, Janssen, Harry L.A., Pojoga, Cristina, Gadano, Adrian, Popescu, Corneliu P., Stepanova, Tatyana, Asselah, Tarik, Diaconescu, Gheorghe, Yim, Hyung Joon, Heo, Jeong, Janczewska, Ewa, Wong, Alexander, Idriz, Nevin, Imamura, Michio, Rizzardini, Giuliano, Takaguchi, Koichi, Andreone, Pietro, Arbune, Manuela, Hou, Jinlin, Park, Sung Jae, Vata, Andrei, Cremer, Jennifer, Elston, Robert, Lukić, Tamara, Quinn, Geoff, Maynard, Lauren, Kendrick, Stuart, Plein, Helene, Campbell, Fiona, Paff, Melanie, Theodore, Dickens
Format Journal Article
LanguageEnglish
Published United States Massachusetts Medical Society 24.11.2022
Subjects
Alanine transaminase
Antigens
Antisense oligonucleotides
Antiviral Agents - adverse effects
Antiviral Agents - therapeutic use
Antiviral drugs
Chronic infection
DNA, Viral - blood
Fever
Gastroenterology
Gastroenterology General
Genetics
Hepatitis
Hepatitis B
Hepatitis B e Antigens - blood
Hepatitis B surface antigen
Hepatitis B Surface Antigens - blood
Hepatitis B virus - genetics
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - virology
Humans
Hypothesis testing
Infections
Infectious Disease
Injections, Subcutaneous
International organizations
Laboratories
Liver cancer
Liver Disease
Liver diseases
Nucleoside analogs
Nucleotide analogs
Oligonucleotides, Antisense - administration & dosage
Oligonucleotides, Antisense - adverse effects
Oligonucleotides, Antisense - therapeutic use
Placebos
Response rates
RNA Therapeutics
RNA, Messenger - drug effects
RNA, Viral - drug effects
Treatment Outcome
Viral Infections
Online AccessGet full text

Cover

More Information
Summary:In a phase 2 trial, bepirovirsen, an antisense oligonucleotide that targets all hepatitis B virus mRNAs, resulted in sustained loss of hepatitis B surface antigen and HBV DNA in 9 to 10% of participants with chronic HBV infection.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Article-2
ObjectType-Feature-1
content type line 23
ObjectType-Undefined-3
ISSN:0028-4793
1533-4406
1533-4406
DOI:10.1056/NEJMoa2210027